| |
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use.
|
|
Today’s Big NewsDec 10, 2024 |
|
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now.
|
|
| By Angus Liu With a positive phase 3 trial in chronic lymphocytic leukemia, Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following another drug in the class—into a full nod. |
|
|
|
By Gabrielle Masson After receiving an unsolicited acquisition proposal from an unnamed Big Pharma in 2023, Poseida reached out to inform partner Roche of the offer, at which point the Swiss pharma said it wasn’t interested in buying the biotech at the time. |
By Conor Hale AngioDynamics obtained a green light for its NanoKnife prostate cancer ablation system, designed to target tissue without delivering excess heat. |
By Andrea Park Apparently, it takes three to bring Boehringer Ingelheim and Eli Lilly’s joint “It Takes 2” initiative to the annual Tournament of Roses Parade next month. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success.
|
|
By Zoey Becker The share buyback program comes after a recent $5 billion buyback campaign the company completed during the current quarter. |
By James Waldron GSK has handed over $45 million upfront to fellow London, U.K.-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. |
By Conor Hale Artivion has secured a green light from the FDA for its stentlike implant designed to help remodel the interior of the aortic arch following rare and severe tears within the lining of the major blood vessel. |
By Angus Liu Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug at a disadvantage to AbbVie and Genmab’s subcutaneously injected Epkinly. That formulation gap could be closed soon. |
By Nick Paul Taylor BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial benchmark and supporting use in a broader population. |
By Fraiser Kansteiner Drug ingredients specialist EuroAPI on Monday said it had accepted the resignation of Ludwig de Mot as CEO. In turn, the company has appointed its chief operating officer, David Seignolle, to immediately take up the helm as CEO. |
By James Waldron Lava Therapeutics has jettisoned its only wholly owned clinical-stage asset after the blood cancer drug “did not reach Lava’s internal benchmarks.” |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
|
|---|
|
|
|
The DMPK experts at QPS are ready to complete your next mass balance,
PK, ADME, MARG and/or QWBA study. Download the DMPK White Paper on the optimal methods of producing tissue distribution data and to learn more about QPS DMPK capabilities.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
